SE0102887D0 - New formulation - Google Patents

New formulation

Info

Publication number
SE0102887D0
SE0102887D0 SE0102887A SE0102887A SE0102887D0 SE 0102887 D0 SE0102887 D0 SE 0102887D0 SE 0102887 A SE0102887 A SE 0102887A SE 0102887 A SE0102887 A SE 0102887A SE 0102887 D0 SE0102887 D0 SE 0102887D0
Authority
SE
Sweden
Prior art keywords
dosage form
relates
active substance
extended release
release oral
Prior art date
Application number
SE0102887A
Other languages
English (en)
Swedish (sv)
Inventor
Karin Ellstroem
Ulf Kjellberg
Haakan Nyquist
Anders Ringberg
Annika Schweighofer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102887A priority Critical patent/SE0102887D0/xx
Publication of SE0102887D0 publication Critical patent/SE0102887D0/xx
Priority to BR0212167-0A priority patent/BR0212167A/pt
Priority to CNA028168712A priority patent/CN1549705A/zh
Priority to CA002457341A priority patent/CA2457341A1/fr
Priority to KR10-2004-7002920A priority patent/KR20040032977A/ko
Priority to HU0401599A priority patent/HUP0401599A3/hu
Priority to US10/488,125 priority patent/US20040197404A1/en
Priority to MXPA04001805A priority patent/MXPA04001805A/es
Priority to IL16037102A priority patent/IL160371A0/xx
Priority to PCT/SE2002/001541 priority patent/WO2003017983A1/fr
Priority to EP02763155A priority patent/EP1423099A1/fr
Priority to JP2003522503A priority patent/JP2005504052A/ja
Priority to ZA200401547A priority patent/ZA200401547B/en
Priority to NO20040857A priority patent/NO20040857L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
SE0102887A 2001-08-29 2001-08-29 New formulation SE0102887D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE0102887A SE0102887D0 (sv) 2001-08-29 2001-08-29 New formulation
JP2003522503A JP2005504052A (ja) 2001-08-29 2002-08-28 新規の徐放性経口製剤
US10/488,125 US20040197404A1 (en) 2001-08-29 2002-08-28 Extended release oral dosage form
CNA028168712A CN1549705A (zh) 2001-08-29 2002-08-28 新的缓释口服剂型
CA002457341A CA2457341A1 (fr) 2001-08-29 2002-08-28 Nouvelle forme posologique orale a liberation prolongee
KR10-2004-7002920A KR20040032977A (ko) 2001-08-29 2002-08-28 신규 지연 방출 경구 투여 제형
HU0401599A HUP0401599A3 (en) 2001-08-29 2002-08-28 Extended release oral dosage form
BR0212167-0A BR0212167A (pt) 2001-08-29 2002-08-28 Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada
MXPA04001805A MXPA04001805A (es) 2001-08-29 2002-08-28 Nueva forma de dosificacion oral de liberacion prolongada.
IL16037102A IL160371A0 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form
PCT/SE2002/001541 WO2003017983A1 (fr) 2001-08-29 2002-08-28 Nouvelle forme posologique orale a liberation prolongee
EP02763155A EP1423099A1 (fr) 2001-08-29 2002-08-28 Nouvelle forme posologique orale a liberation prolongee
ZA200401547A ZA200401547B (en) 2001-08-29 2004-02-25 A new extended release oral dosage form.
NO20040857A NO20040857L (no) 2001-08-29 2004-02-26 Ny oral forlenget frigivelses doseringsform.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102887A SE0102887D0 (sv) 2001-08-29 2001-08-29 New formulation

Publications (1)

Publication Number Publication Date
SE0102887D0 true SE0102887D0 (sv) 2001-08-29

Family

ID=20285178

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102887A SE0102887D0 (sv) 2001-08-29 2001-08-29 New formulation

Country Status (14)

Country Link
US (1) US20040197404A1 (fr)
EP (1) EP1423099A1 (fr)
JP (1) JP2005504052A (fr)
KR (1) KR20040032977A (fr)
CN (1) CN1549705A (fr)
BR (1) BR0212167A (fr)
CA (1) CA2457341A1 (fr)
HU (1) HUP0401599A3 (fr)
IL (1) IL160371A0 (fr)
MX (1) MXPA04001805A (fr)
NO (1) NO20040857L (fr)
SE (1) SE0102887D0 (fr)
WO (1) WO2003017983A1 (fr)
ZA (1) ZA200401547B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904067B2 (fr) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Formulation pharmaceutique de derives de carboxamide , inhibiteurs de l'hiv integrase, comprenant une composition a liberation contrôlee
EP1946780B1 (fr) 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Preparation solide a liberation controlee
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
AU2012336036A1 (en) * 2011-11-07 2014-06-19 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
US9358204B2 (en) * 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
EP2822542A1 (fr) * 2012-03-07 2015-01-14 Santarus, Inc. Formes posologiques solides à libération contrôlée de mésalamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor

Also Published As

Publication number Publication date
MXPA04001805A (es) 2004-07-08
ZA200401547B (en) 2004-11-17
HUP0401599A2 (hu) 2004-11-29
WO2003017983A1 (fr) 2003-03-06
US20040197404A1 (en) 2004-10-07
CN1549705A (zh) 2004-11-24
HUP0401599A3 (en) 2007-03-28
EP1423099A1 (fr) 2004-06-02
KR20040032977A (ko) 2004-04-17
BR0212167A (pt) 2004-07-20
NO20040857L (no) 2004-04-19
JP2005504052A (ja) 2005-02-10
CA2457341A1 (fr) 2003-03-06
IL160371A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
NO20055880L (no) Memantin orale doseringsformer
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
HK1068606A1 (en) Novel aminobenzoephenones
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
SG146638A1 (en) Pharmaceutical delivery system
HUP0203682A2 (hu) Eljárás foszfodiészteráz-4 inhibitor beadására
SE0102887D0 (sv) New formulation
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
SE9902597D0 (sv) New use
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
SE0102886D0 (sv) New formulation
SE0102888D0 (sv) New formulation
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004043486A8 (fr) Formulation pharmaceutique aqueuse contenant l'inhibiteur de la thrombine melagatran et utilisation de cette formulation pour la preparation d'un medicament a administration nasale destine au traitement de la maladie thrombo-embolique
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
SE0002354D0 (sv) New formulation
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
DE60113895D1 (de) Verwendung von Tiludronsäure beim Geflügel zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von Osteoporose
TH62247A (fr)